SOMNF (SomnoMed) FFO


SOMNF SomnoMed Ltd SOMNF
49 GF Score
Price $0.45
GF Value $0.33
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is SomnoMed FFO?

FFO (Funds from operations) only applies to REITs.

SOMNF
49GF Score
SomnoMed Ltd SOMNF
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is SomnoMed (SOMNF) Overvalued in 2026?

Based on GuruFocus' analysis, SomnoMed stock appears to be overvalued. The current stock price of $0.45 is trading 35.7% above its estimated GF Value™ of $0.33. GuruFocus considers SomnoMed to be Significantly Overvalued.

Key valuation signals for SOMNF:

  • FFO:
  • GF Value™: $0.33 vs. price of $0.45 (35.7% above fair value)
  • GF Score™: 49/100 with 3 warning signs

No single metric tells the full story. See the SOMNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

SomnoMed Business Description

Other Exchanges RJV:GermanySOM:Australia
Address 20 Clarke Street, Level 3, Crows Nest, Sydney, NSW, AUS, 2065
SomnoMed Ltd provides treatment solutions for sleep-related breathing disorders, including obstructive sleep apnea, snoring, and bruxism. It is engaged in commercializing SomnoDent Mandibular Advancement Splint (MAS) and other oral devices for sleep-related disorders in Australia and overseas. The other products in the company's portfolio include SomMorning Repositioner; SomnoBrux splint, a custom-fit, acrylic splint (dental guard) for upper teeth designed to protect teeth from grinding and scraping during Bruxism; and SomTabs cleaning tablets that have been developed to clean oral appliances. Geographically, the company generates maximum revenue from Europe, followed by North America and the Asia Pacific region.
49GF Score

Get the complete analysis for SOMNF

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.45
Price
$0.33
GF Value